AA
KYTX icon

ALPS Advisors’s Kyverna Therapeutics KYTX Stock Holding History

ALPS Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,126
Closed -$62K – 1064
2025
Q1 		$62K Sell
32,126
-2,786
-8% -$8.23K ﹤0.01% 984
2024
Q4 		$131K Buy
34,912
+1,856
+6% +$8.89K ﹤0.01% 983
2024
Q3 		$162K Sell
33,056
-573
-2% -$4.42K ﹤0.01% 984
2024
Q2 		$252K Buy
+33,629
New +$514K ﹤0.01% 930

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ALPS Advisors's KYTX Position: Q2 2025 in Review

ALPS Advisors sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 32,126 shares — an estimated $62K sold.

ALPS Advisors first reported a position in KYTX in Q2 2024 and held it in 4 quarters. The position peaked at $252K in Q2 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • ALPS Advisors reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 32,126 Kyverna Therapeutics shares in Q2 2025, an estimated $62K.
  • ALPS Advisors first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 4 quarters.
  • ALPS Advisors's Kyverna Therapeutics position peaked at $252K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.